Page 18 - Data Collective News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 802 Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round. The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed...

Alchemab completes £60m Series A funding to advance novel antibody platform 15th April 2021 Cambridge, UK-based Alchemab Therapeutics has raised £60m ($82m) in a Series A funding round, in a bid to advance its target-agnostic drug discovery platform. The firm announced that the round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC, DHVC, SV Health Investors and the Dementia Discovery Fund. The funding will be used to advance Alchemab’s novel platform, designed to identify disease-modifying antibody therapeutics, the company said in a state...

Alchemab Therapeutics Raises £60M in Series A Financing Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round. The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company, which was created by SV Health Investors who led the Seed round in 2019, intends to use the advance its target-agnostic drug discove...

Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer Share Rare Daily Staff Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, said it closed an $82 million (£60 million) series A financing round. RA Capital Management led the financing, with participation by an international syndicate that included Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors, and the Dementia Discovery Fund. The company was ...

(1) Distinguished leader Steve Neat joins Alation to accelerate growth and regional expansion, enhance customer intimacy Alation Inc., the leader in enterprise data intelligence solutions, today announced the appointment of Steve Neat as its new Vice President of Sales for Europe, the Middle East, and Africa (EMEA). Steve will address the ever-increasing demand for Alation in EMEA; develop new sales channels; and contribute to strategies that drive business value for Alation's international customers. "I am excited to have a deep-rooted industry executive like Steve join the Alation team...